362 related articles for article (PubMed ID: 23918944)
1. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
Phillips KA; Milne RL; Rookus MA; Daly MB; Antoniou AC; Peock S; Frost D; Easton DF; Ellis S; Friedlander ML; Buys SS; Andrieu N; Noguès C; Stoppa-Lyonnet D; Bonadona V; Pujol P; McLachlan SA; John EM; Hooning MJ; Seynaeve C; Tollenaar RA; Goldgar DE; Terry MB; Caldes T; Weideman PC; Andrulis IL; Singer CF; Birch K; Simard J; Southey MC; Olsson HL; Jakubowska A; Olah E; Gerdes AM; Foretova L; Hopper JL
J Clin Oncol; 2013 Sep; 31(25):3091-9. PubMed ID: 23918944
[TBL] [Abstract][Full Text] [Related]
2. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Kuchenbaecker KB; Hopper JL; Barnes DR; Phillips KA; Mooij TM; Roos-Blom MJ; Jervis S; van Leeuwen FE; Milne RL; Andrieu N; Goldgar DE; Terry MB; Rookus MA; Easton DF; Antoniou AC; ; McGuffog L; Evans DG; Barrowdale D; Frost D; Adlard J; Ong KR; Izatt L; Tischkowitz M; Eeles R; Davidson R; Hodgson S; Ellis S; Nogues C; Lasset C; Stoppa-Lyonnet D; Fricker JP; Faivre L; Berthet P; Hooning MJ; van der Kolk LE; Kets CM; Adank MA; John EM; Chung WK; Andrulis IL; Southey M; Daly MB; Buys SS; Osorio A; Engel C; Kast K; Schmutzler RK; Caldes T; Jakubowska A; Simard J; Friedlander ML; McLachlan SA; Machackova E; Foretova L; Tan YY; Singer CF; Olah E; Gerdes AM; Arver B; Olsson H
JAMA; 2017 Jun; 317(23):2402-2416. PubMed ID: 28632866
[TBL] [Abstract][Full Text] [Related]
3. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
[TBL] [Abstract][Full Text] [Related]
4. Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.
Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Weideman PC; Birch KE; Hopper JL; Phillips KA
J Clin Oncol; 2013 Nov; 31(31):3920-5. PubMed ID: 24081944
[TBL] [Abstract][Full Text] [Related]
5. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
[TBL] [Abstract][Full Text] [Related]
6. Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Kotsopoulos J; Huzarski T; Gronwald J; Singer CF; Moller P; Lynch HT; Armel S; Karlan B; Foulkes WD; Neuhausen SL; Senter L; Tung N; Weitzel JN; Eisen A; Metcalfe K; Eng C; Pal T; Evans G; Sun P; Lubinski J; Narod SA;
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27601060
[TBL] [Abstract][Full Text] [Related]
7. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman P; Milne RL; McLachlan SA; Hopper JL; Phillips KA
Breast Cancer Res Treat; 2010 Apr; 120(3):715-23. PubMed ID: 19669874
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.
Gronwald J; Tung N; Foulkes WD; Offit K; Gershoni R; Daly M; Kim-Sing C; Olsson H; Ainsworth P; Eisen A; Saal H; Friedman E; Olopade O; Osborne M; Weitzel J; Lynch H; Ghadirian P; Lubinski J; Sun P; Narod SA;
Int J Cancer; 2006 May; 118(9):2281-4. PubMed ID: 16331614
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
Narod SA; Brunet JS; Ghadirian P; Robson M; Heimdal K; Neuhausen SL; Stoppa-Lyonnet D; Lerman C; Pasini B; de los Rios P; Weber B; Lynch H;
Lancet; 2000 Dec; 356(9245):1876-81. PubMed ID: 11130383
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.
Peshkin BN; Isaacs C; Finch C; Kent S; Schwartz MD
J Clin Oncol; 2003 Dec; 21(23):4322-8. PubMed ID: 14645421
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
Drooger J; Akdeniz D; Pignol JP; Koppert LB; McCool D; Seynaeve CM; Hooning MJ; Jager A
Breast Cancer Res Treat; 2015 Nov; 154(1):171-80. PubMed ID: 26467044
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
Kuchenbaecker KB; McGuffog L; Barrowdale D; Lee A; Soucy P; Dennis J; Domchek SM; Robson M; Spurdle AB; Ramus SJ; Mavaddat N; Terry MB; Neuhausen SL; Schmutzler RK; Simard J; Pharoah PDP; Offit K; Couch FJ; Chenevix-Trench G; Easton DF; Antoniou AC
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376175
[TBL] [Abstract][Full Text] [Related]
13. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
Metcalfe KA; Birenbaum-Carmeli D; Lubinski J; Gronwald J; Lynch H; Moller P; Ghadirian P; Foulkes WD; Klijn J; Friedman E; Kim-Sing C; Ainsworth P; Rosen B; Domchek S; Wagner T; Tung N; Manoukian S; Couch F; Sun P; Narod SA;
Int J Cancer; 2008 May; 122(9):2017-22. PubMed ID: 18196574
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.
Xu L; Zhao Y; Chen Z; Wang Y; Chen L; Wang S
Breast Cancer; 2015 Jul; 22(4):327-34. PubMed ID: 26022977
[TBL] [Abstract][Full Text] [Related]
15. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Gronwald J; Robidoux A; Kim-Sing C; Tung N; Lynch HT; Foulkes WD; Manoukian S; Ainsworth P; Neuhausen SL; Demsky R; Eisen A; Singer CF; Saal H; Senter L; Eng C; Weitzel J; Moller P; Gilchrist DM; Olopade O; Ginsburg O; Sun P; Huzarski T; Lubinski J; Narod SA;
Breast Cancer Res Treat; 2014 Jul; 146(2):421-7. PubMed ID: 24951267
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Reding KW; Bernstein JL; Langholz BM; Bernstein L; Haile RW; Begg CB; Lynch CF; Concannon P; Borg A; Teraoka SN; Törngren T; Diep A; Xue S; Bertelsen L; Liang X; Reiner AS; Capanu M; Malone KE;
Breast Cancer Res Treat; 2010 Sep; 123(2):491-8. PubMed ID: 20135344
[TBL] [Abstract][Full Text] [Related]
17. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.
Akdeniz D; van Barele M; Heemskerk-Gerritsen BAM; Steyerberg EW; Hauptmann M; ; van de Beek I; van Engelen K; Wevers MR; Gómez García EB; Ausems MGEM; Berger LPV; van Asperen CJ; Adank MA; Collée MJ; Stommel-Jenner DJ; Jager A; Schmidt MK; Hooning MJ
Breast; 2022 Feb; 61():98-107. PubMed ID: 34929424
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
[TBL] [Abstract][Full Text] [Related]
19. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Kauff ND; Domchek SM; Friebel TM; Robson ME; Lee J; Garber JE; Isaacs C; Evans DG; Lynch H; Eeles RA; Neuhausen SL; Daly MB; Matloff E; Blum JL; Sabbatini P; Barakat RR; Hudis C; Norton L; Offit K; Rebbeck TR
J Clin Oncol; 2008 Mar; 26(8):1331-7. PubMed ID: 18268356
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.
Kotsopoulos J; Gronwald J; Huzarski T; Aeilts A; Randall Armel S; Karlan B; Singer CF; Eisen A; Tung N; Olopade O; Bordeleau L; Eng C; Foulkes WD; Neuhausen SL; Cullinane CA; Pal T; Fruscio R; Lubinski J; Metcalfe K; Sun P; Narod SA;
Breast Cancer Res Treat; 2023 Sep; 201(2):257-264. PubMed ID: 37432545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
